Private company

Ortho Clinical Diagnostics Holdings plc

British in vitro and in vivo diagnostic substances company, active since 19902

In its 2022 annual report the company says: “We are a pure-play in vitro diagnostics business, pioneering life-impacting advances in diagnostics for over 80 years, from our earliest work in blood typing, to our innovation in infectious diseases and our latest developments in laboratory solutions. We are driven by our credo, “Because Every Test is A Life. We are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communities.”36 It is headquartered in High Wycombe, United Kingdom.2

Last updated Oct 20, 2026.

Overview

$2.0BRevenue, fiscal 20223
-$54.3MNet income, fiscal 20223
  • IndustryIn Vitro & In Vivo Diagnostic Substances2
  • HeadquartersHigh Wycombe, United Kingdom2
  • Incorporated inUnited Kingdom4
  • Business address1001 Route 202, Raritan, Nj 088694
  • Filer categoryNon-accelerated filer4
  • Legal formPrivate Unlimited2
  • LEI549300ZZX9WCBZNYL8492
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressFelindre Meadows, CF35 5PZ Bridgend, United Kingdom2
  • Registered withCompanies House, 025497772

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

8.5%Operating margin3
-2.7%Net margin3
15.7%Revenue growth, 20223
-13.2%Return on equity3
5.55×Debt to equity3
$228.2MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue49¢$1.0B
  • Research and development6¢$126.2M
  • Selling, general and admin27¢$555.0M
  • Other costs9¢$180.5M
  • Interest7¢$146.0M
  • Income tax1¢$28.3M

Out of $2.0B in revenue.3 The company lost money this year.

Where each dollar of operating cash went, fiscal 2022

  • Capital spending20¢$58.4M
  • Kept or used elsewhere80¢$228.2M

Out of $286.6M of cash from operations.3

Financial statements

Revenue3$2.0B in 2022+13% since 2019
0$1.0B$2.0B$3.0B2019: $1.8B$1.8B20192021: $1.8B$1.8B2021−2%2022: $2.0B$2.0B2022+16%
Operating income3$173.9M in 2022+103% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $85.5M$85.5M20192021: $88.3M$88.3M2021+3%2022: $173.9M$173.9M2022+97%
Net income3-$54.3M in 2022−65% since 2019
-$300.0M-$200.0M-$100.0M02019: -$156.9M-$156.9M20192021: -$211.9M-$211.9M2021+35%2022: -$54.3M-$54.3M2022−74%
Fiscal year2018201920212022
Revenue$1.8B3$1.8B3$2.0B3
Cost of revenue$922.4M3$908.2M3$1.0B3
Research and development$98.0M3$112.9M3$126.2M3
Selling, general and admin$515.1M3$489.6M3$555.0M3
Operating income$85.5M3$88.3M3$173.9M3
Interest$231.4M3$198.2M3$146.0M3
Income before tax-$26.0M3
Income tax-$23.9M3-$13.4M3$28.3M3
Net income-$156.9M3-$211.9M3-$54.3M3

Compare Ortho Clinical Diagnostics Holdings plc with another company

Corporate structure

Ortho Clinical Diagnostics Holdings plc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Ortho Clinical Diagnostics Holdings plc

  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G on Ortho Clinical Diagnostics Holdings plc, latest Feb 14, 2022
  • Ortho Clinical Diagnostics Holdings plc High Wycombe, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Ortho Clinical Diagnostics Holdings plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.9B3 Jan 2, 2022$1.8B3 Jan 3, 2021+5.7%
Accumulated depreciation$1.1B3 Jan 2, 2022$968.4M3 Jan 3, 2021+14.7%
Property and equipment, net$791.4M3 Jan 2, 2022$832.0M3 Jan 3, 2021−4.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$309.7M3 Jan 2, 2022$132.8M3 Jan 3, 2021+133.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$573.6M3 Jan 2, 2022$580.1M3 Jan 3, 2021−1.1%
Intangible assets, net (excluding goodwill)$879.2M3 Jan 2, 2022$1.0B3 Jan 3, 2021−13.5%
Finite-lived intangibles, gross$2.0B3 Jan 2, 2022$2.0B3 Jan 3, 2021−0.5%
Accumulated amortization$1.1B3 Jan 2, 2022$947.0M3 Jan 3, 2021+13.5%
Finite-lived intangibles, net$879.2M3 Jan 2, 2022$1.0B3 Jan 3, 2021−13.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$305.4M3 Jan 2, 2022$278.7M3 Jan 3, 2021+9.6%
Work in process$32.4M3 Jan 2, 2022$35.2M3 Jan 3, 2021−8.0%
Finished goods$196.5M3 Jan 2, 2022$166.3M3 Jan 3, 2021+18.2%

Leadership

Who has led Ortho Clinical Diagnostics Holdings plc, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Joseph M. Busky2021–2022

Chief operating officer

  1. Chad Dale2021
2025
Board members and other officers (12)

Former names

  • Ortho-Clinical Diagnostics Bermuda Co. Ltd.Oct 16, 2020 to Dec 15, 20204

Timeline

  1. May 27, 20228-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale21
  2. May 26, 20228-K Executive or director change22
  3. May 20, 20228-K Shareholder vote; Other events23
  4. May 20, 20228-K Regulation FD disclosure24
  5. May 19, 20228-K Regulation FD disclosure25
  6. May 18, 20228-K Regulation FD disclosure26
  7. May 16, 20228-K Other events27
  8. May 6, 20228-K Other events28
  9. May 4, 20228-K Results of operations29
  10. Apr 7, 20228-K Executive or director change30
  11. Feb 16, 20228-K Executive or director change31
  12. Feb 16, 20228-K Results of operations32
  13. Oct 18, 1990Founded Ortho Clinical Diagnostics Holdings plc is founded2

Calendar

When it reported results

  1. May 4, 2022Reported quarterly or annual results29
  2. Feb 16, 2022Reported quarterly or annual results32
  3. Jan 6, 2022Reported quarterly or annual results33
  4. Nov 3, 2021Reported quarterly or annual results34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

55 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 19 major events, 21 insider forms, 1 large holders, 11 other. The latest 20:

  1. Jun 6, 202215-12B EDGAR
  2. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  3. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  4. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  5. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  6. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  7. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  8. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  9. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  10. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  11. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  12. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  13. Jun 1, 20224 FORM 4 SUBMISSION EDGAR
  14. May 31, 20224 FORM 4 SUBMISSION EDGAR
  15. May 27, 20228-K EDGAR
  16. May 26, 20228-K EDGAR
  17. May 20, 20228-K EDGAR
  18. May 20, 20228-K/A EDGAR
  19. May 19, 20228-K/A EDGAR
  20. May 18, 20228-K EDGAR

The 55 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 4, 2022Schlesinger Michael A.EVP, GC and SecretarySale88,043$18.77$1.7MForm 4
Jan 3, 2022Smith Christopher MChairman and CEOSale100,000$21.10$2.1MForm 4
Jan 3, 2022Schlesinger Michael A.EVP, GC and SecretarySale130,000$21.09$2.7MForm 4
Oct 15, 2021Schlesinger Michael A.EVP, GC and SecretarySale75,464$19.73$1.5MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Ortho Clinical Diagnostics Holdings plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROrtho Clinical Diagnostics Holdings plc1
  • CIK0001828443
  • Employer ID (EIN)98-11518191
  • Filer statusNon-accelerated filer1
  • Incorporated inUnited Kingdom1
  • Fiscal year endsJanuary 21
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • Business address1001 Route 202, Raritan, NJ 088691
  • Phone(908) 218-80001
  • Shares outstanding237,734,877 as of Apr 29, 20226
  • Public float$1.9B as of Jul 4, 20213
  • On EDGAR sinceOct 16, 20201
  • Filings147 in all: 4 (34), 8-K (30), 425 (23), 3 (17), UPLOAD (6), CORRESP (5), 10-Q (4), 10-K (2)1
    All 26 form types

    424B4 (2), 8-K/A (2), DRS (2), DRS/A (2), DRSLTR (2), EFFECT (2), S-1 (2), SC 13G (2), 15-12B (1), 25-NSE (1), 8-A12B (1), CERT (1), DEF 14A (1), DEFA14A (1), DEFM14A (1), S-1/A (1), S-1MEF (1), S-8 (1)

  • Latest filingsAnnual report (10-K) Mar 8, 2022
    Quarterly report (10-Q) May 10, 2022
    Proxy statement (DEF 14A) May 2, 2022
    Latest 8-K (8-K) May 27, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36